Period:
Draw Mode:
| Volume | 83,159 |
|
|||||
| News | - |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Immutep Ltd | IMMP | NASDAQ | Depository Receipt |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.02 | 1.02% | 1.99 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.97 | 1.93 | 1.9874 | 1.98 | 1.97 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume |
|---|---|---|---|---|
| 408 | 83,159 | 1.96 | 163,374 | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:43:54 | 89 | 1.94 | USD |
Immutep Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.36B | 1.19B | - | 0 | -39.9M | 0.00 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News Immutep
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
IMMP Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's unique ability to stimulate or suppress the immune response. Immutep's lead clinical candidate, eftilagimod alpha ('efti'), is a soluble LAG-3 protein and first-in-class MHC Class II agonist that stimulates both innate and adaptive immunity to fight cancer. |